

General Population Screening for T1D

6th Symposium
November 9-10, 2023



Barbara Davis Center for Diabetes
UNIVERSITY OF COLORADO SCHOOL OF MEDICINE

6th Childhood Diabetes Prevention Symposium
General Population Screening for T1D

November 9-10, 2023

Anschutz Medical Campus, Aurora, Colorado, USA

Friday

- | | |
|-------------------|---|
| 8-9 | Priorities and challenges in population screening for T1D |
| 9-12:30 | Reports from current general population screening programs |
| 12:30-1:00 | lunch |
| 1-2:30 | Standardization of immune markers for screening |
| 2:45-4:40 | Guidelines for monitoring and education in pre-T1D |

Thank you

This program was developed independently by the Barbara Davis Center for Diabetes and supported in part by educational grants from Sanofi US and the Children's Diabetes Foundation.



Practical issues

- If you are participating by Zoom, type questions in the Q&A window
- The symposium recording will be posted on the website within 10 days; use this QR:



- Please try to keep in-room audience sound to a minimum

Practical issues

- Please direct logistic questions to:
Christy Vasey
Christy.Vasey@cuanschultz.edu 303 803-8887
- Please direct audio-visual or IT questions to:
Josh Hartz
Joshua.Hartz@cuanschultz.edu 303 591-0345



Thank you!

Priorities and Challenges in Population Screening for T1D

Questions to Panelists from the NIH, JDRF, and Helmsley Charitable Trust




National Institute of
Diabetes and Digestive
and Kidney Diseases

Beena Akolkar, PhD, Program Director



Sanjoy Dutta, PhD, Chief Scientific Officer

Esther Latres, PhD, Vice President, Research



Gina Agiostratidou, PhD, Program Director

Anne Koralova, PhD, Program Officer

Who should be screened for islet autoantibodies?

Currently recommended by the ADA:

- People with a family history of T1D
- People w/o family history participating in research studies (e.g., ASK)
- Children with a high T1D GRS participating in research studies

Clinically acceptable

- People with an autoimmune condition and their relatives
- People with dysglycemia or symptoms suggesting undiagnosed diabetes

Likely accepted in the near future

- All children and adolescents
- Adults (age limit?)

1. Are we ready to recommend routine screening of general population children for islet autoantibodies? If not quite yet, what are the barriers?

2. Are we ready to recommend routine screening of general population adults for islet autoantibodies?

3. What are your organization's priorities in the area of T1D screening, in the next 1-3 years?